Advertisement

Topics

Zymeworks Announces License Agreement with Johnson & Johnson Innovation to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics

05:00 EST 13 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Zymeworks licenses the Azymetric™ and EFECT™ platforms to Janssen US$50 million upfront license fee paid to Zymeworks for up to six bispecific programs Zymeworks Inc. (NYSE/TSX:...

Other Sources for this Article

Zymeworks Inc.
Investor Inquiries:
Ryan Dercho, Ph.D.
(604) 678-1388
ir@zymeworks.com
or
Media Inquiries:
Angela Bitting
(925) 202-6211
a.bitting@comcast.net

NEXT ARTICLE

More From BioPortfolio on "Zymeworks Announces License Agreement with Johnson & Johnson Innovation to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...